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Introduction: Burn wound infections (BWI) result in delayed healing and increased pain, 
scarring, sepsis risk and healthcare costs. Clinical decision making about BWI should be 
supported by evidence syntheses. Validity of evidence from systematic reviews may be 
reduced if definitions of BWI vary between trials. This review aimed to determine whether 
BWI is defined, and whether there is variation in the indicators used to define BWI across 
studies testing interventions for patients with burns. 
Method: Searches were carried out in four databases (Ovid Medline, Ovid Embase, Cinahl, 
Cochrane Register of Trials) to identify studies evaluating interventions for patients with 
burns and reporting a BWI outcome. Pre-defined inclusion and exclusion criteria were 
systematically applied to select relevant studies. Data were systematically extracted and 
reported narratively. 
Results: 2056 studies were identified, of which 72 met the inclusion criteria, comprising 71 
unique datasets. 52.1% of studies were randomised controlled trials. Twenty-eight (38.0%) 
studies reporting a BWI outcome did not report how they had defined it. In the methods of 
included studies, 59 studies (83.1%) reported that they planned to measure BWI as an 
outcome. Of these, 44 studies (74.6%) described how they had defined BWI; 6 Studies 
(13.6%) reported use of a previously developed consensus-informed definition of BWI, and 
41 studies (69.5%) described the specific indicators used to define it. Studies used between 
one (11 studies; 26.8%) and nine indicators (2 studies; 4.9%) to define BWI (median=3, 
Inter-quartile range=2). The most commonly used indicator was presence of bacteria in the 
wound (61.0% of studies). Only 13 studies (31.7%) defined BWI using the same indicators as 
at least one other study.  
 
 
Discussion and Conclusions: Within intervention studies reporting BWI outcomes, a 
definition of this outcome is commonly not provided, or it varies between studies. This will 
prevent evidence synthesis to identify effective treatments for patients with burn injuries. 
Since there is no objective method for assessing BWI, expert consensus is needed to agree a 
minimum set of indicators (Core Indicator Set) reported in all trials reporting BWI as an 
outcome.  
 







Wound infections complicate recovery after burn injury and result in increased pain, scarring, risks of 
sepsis and increased healthcare costs [1]. In patients with burns of more than 40% body surface area 
(BSA), it is estimated that 75% of mortality is related to infections[2, 3]. To identify effective 
treatments to prevent, detect or treat BWI, evidence from systematic reviews is needed. Systematic 
reviews aggregate data from several trials of interventions, and are viewed as the best quality 
evidence upon which to base clinical decision making [4, 5].  Challenges with evidence synthesis 
include heterogeneity of outcome definitions across trials. If the definition of the outcome of interest 
varies between studies, or is not stated, the validity of the aggregated data may be compromised, 
because researchers may not be comparing like with like[6]. Variation in how the same outcomes are 
defined has been identified in a review of clinical outcomes reported in randomised trials of burn care 
interventions[7]. For example, the authors identified 166 ways of defining burn wound healing across 
147 studies. It is unclear if a similar heterogeneity in the definition of BWI exists across burn care 
studies. 
One reason for hypothesising that variations in the definition of BWI may exist is that there is no 
agreed objective method for diagnosing BWI. Diagnosis is typically based on clinician judgement, 
supported by data from clinical indicators. These include wound-related or systemic, patient-reported 
symptoms, observer-reported signs, non-specific laboratory tests indicating inflammation and wound 
microscopy to assess the quantity and type of microbes in the wound. Determination of wound 
colonisation typically takes 48 hours or longer. A decision about whether to treat BWI with 
superficial debridement or broad spectrum antibiotics is therefore commonly made before these data 
are available[8]. To support consistent diagnosis of BWI, consensus statements have been developed 
by the American Burns Association (ABA[3]), Center for Disease Control (CDC[9]) and European 
Wound Management Association (EWMA[10]). However, there are practical limitations that preclude 
their routine use in clinical care. For example, the ABA and CDC criteria require the use of a wound 
biopsy. It will be difficult to report data relating to this criterion where wound biopsy is not routinely 
used, due to risks of scarring and the need for anaesthesia. For example, in the UK wound biopsy is 
 
 
rarely used to determine presence of BWI[11]  The EWMA tool states sensitive, but rarely observed, 
wound-related signs as indicators for BWI (e.g. ecthyma gangrenosum), and without reference to 
systemic indicators of infection. These inherent difficulties with diagnosis of BWI are likely to lead to 
the use of varying definitions of BWI across trials in burn care. 
The aim of this systematic review was to determine whether BWI is defined as an outcome, and 
whether there is variation in indicators used to define BWI across studies testing interventions for 
patients with burns.  
 
Method: 
Methods for this review were specified in advance and the protocol registered on the PROSPERO 
database: REF CRD4201809664. We adhered to the PRISMA statement for reporting systematic 
reviews[12]. 
 
Study identification and selection: 
Inclusion and exclusion criteria 
We identified peer reviewed journal articles published between 1st January 2010 and 30th November 
2016, in English, and meeting the following PICOS criteria (Population, Intervention, Control, 
Outcome, Study design):  
i. Participants: studies reporting data from patients with acute burn wounds (before 
healing). Studies with mixed populations where patients had both burn and other 
traumatic injuries were excluded, unless data relating to patients with burns were 
presented separately.  
ii. Intervention and control groups: Studies reporting any intervention to treat patients with 
burn injury and any comparator intervention or standard care were included.  
 
 
iii. Outcomes of interest: Studies reporting BWI as an outcome in the abstract, methods, 
results or discussion were included.  We accepted any study where the authors used the 
terms ‘burn wound infection’ or ‘wound infection’. 
iv. Study design: Studies were included if they employed a randomised controlled trial, 
controlled trial, observational study design, case control study or reported a protocol for a 
trial or observational study. 
 
INSERT Table 1: Exclusion criteria for selection of studies  
 
Electronic search 
An electronic search of four databases was carried out to identify relevant studies: Cinahl, Ovid 
Embase, Ovid MEDLINE, Cochrane Register of Controlled Trials (CENTRAL). To identify studies 
that met the inclusion criteria, three groups of search terms were iteratively developed relating to 
burns, wound infection, interventions and trials. Medical Subject Headings (MeSH) were used where 
available. Synonyms for each term were combined using an OR term, and the groups of terms were 
combined using an AND term. Following piloting of the search strategy in two databases (Ovid 
Embase and Ovid MEDLINE), NOT terms were added to increase the specificity of the search, thus 
removing studies irrelevant to the topic (e.g. NOT Coxiella Burnetii, burnout). The search string used 
in Medline is presented in Table 2. This was modified for each database. The search terms were 
applied to the title, abstract and keywords where possible, to increase the specificity of the search.  
INSERT Table 2: Search terms in Medline 
 
Selection of papers for inclusion: 
Search results were downloaded from each database and combined in an Endnote database (version 
8), where records were manually reviewed to remove duplicates. Citations were exported to a 
 
 
Microsoft Excel database for screening. First, titles and abstracts were reviewed against the exclusion 
criteria. Next, full text articles of retained citations were obtained and screened using the same 
criteria.  For both screening stages a second researcher (FSJ) screened 20% of citations. 
Data extraction 
A proforma to standardise data extraction was developed in Microsoft Excel and piloted for 
comprehensiveness and clarity. Where the same dataset was reported across two or more studies, 
extracted data about the studies were combined as a single dataset. Data extraction from 20% of 
papers was checked by a second researcher (FSJ) to ensure reliability.  
Extracted data to describe each study were: i) study identifiers (title, authors, date and citation), ii) 
study design, iii) intervention/s and control condition/s evaluated.  
For each study, data were extracted about study methods and indicators used to define BWI. Data 
extracted were: 
i) Whether BWI was defined in the study methods or results, ie. it reported a diagnostic tool 
(consensus statement) or the indicators used for diagnosis.  
ii) A verbatim report of each indicator used to define BWI. We accepted author-defined 
BWI, whether the indicators were those typically used to define BWI or not. Each 
indicator wase categorised under a label to allow summary and comparison of data (see 
below). The number of indicators used to define BWI were noted for each study.  
iii) Whether the same indicators were used to define BWI across studies.  
iv) Whether numerical values were reported for indicators to determine presence of BWI  
v) Whether a method for combining data from several indicators to determine presence of 






Examination of the verbatim data from (ii) to describe the BWI indicators used in each study 
demonstrated that for some indicators of BWI, terminology used to describe the same indicator varied 
across studies. To enable a count of the indicators used, and identify common indicators used across 
studies, a process was undertaken by two reviewers (AD, FSJ) to group such indicators under a 
consistent label. For example, if different studies had described an indicator as ‘wound microscopy 
from swab’,‘bacteria in wound identified using swab’, ‘swab of wound pus’, these indicators were 
assigned the same label ‘bacteria in wound swab identified from pus or exudate’.  Similarly, where 
studies had used the term ‘spreading erythema’, ‘erythema’, ‘redness in surrounding tissue’, these 
were assigned the label ‘spreading erythema’. 
A small number of studies reported defining BWI using an indicator that represented a group of signs 
or symptoms, for example ‘clinical signs’, ‘cellulitis’. These indicators were labelled using their 
verbatim terminology. While it is acknowledged that these labelled indicators represent a group of 
signs and symptoms, since it is not known what signs and symptoms the authors referred to, they were 
counted as a single indicator.  
Where studies reported use of a diagnostic tool (e.g. the ABA[3] or CDC[9] consensus statement), the 
indicators used in the tool were not reported as verbatim indicators and are excluded from the counts 
of indicators used to define BWI.  
Data synthesis  
No risk of bias assessment of studies or meta-analysis of outcome data was conducted, since this 
review aimed to report the indicators used to assess presence of BWI across studies and did not aim to 
assess the effectiveness of interventions. A narrative review of the data is presented.  
 
RESULTS 
Results of electronic search  
 
 
The electronic search identified 4314 studies, of which 2258 were duplicates. Following the two 
screening stages, 72 studies, comprising 71 unique datasets met the inclusion criteria (Figure 1). 
Therefore, data from two studies were combined[13, 14]. 
INSERT FIGURE 1 HERE 
Characteristics of included studies 
Table 3 indicates the characteristics of included studies. 
 
INSERT Table 3: Characteristics of included studies 
 
i) Whether BWI was defined in the study  
Fifty-nine studies (83.1%) described that BWI would be assessed as a study outcome in the methods. 
The remaining 12 studies (16.9%) did not describe that they planned to assess this outcome in their 
methods, despite reporting it in the results[15-26]. Forty-four of the 59 (74.6%) studies that stated that 
they planned to assess BWI as a study outcome provided a definition of BWI in the study methods or 
the study results.  Therefore, 15 studies (25.4%) stated that BWI would be assessed, but did not 
describe the indicators used to define it [27-41].   
Six studies (13.6%) reported that they had defined BWI using a consensus tool [42-47]. Four studies 
used the ABA consensus statement[3] (studies:[42, 45, 48, 49]). Two studies reported that they had 
used criteria developed by Peck and colleagues[50] (studies: [46, 47]). One study combined Peck and 
colleagues’ criteria with criteria developed by Silla and colleagues[51] (study: [47]). Three of the 
studies using consensus statements also reported the use of additional specific indicators[42, 45, 47]. 
Therefore, 41 of the 59 studies (69.5%) that stated that they planned to assess BWI defined it using 
one or more indicators of BWI. 
 
ii) Indicators used to define BWI within and across studies 
 
 
The indicators used to define BWI in the 41 studies (69.5%) that reported the use of one or more 
specific indicators are presented in table 4. Twenty-seven different indicators were used to define 
BWI across all these studies. The number of indicators used within studies ranged between one 
(26.8% of studies) and nine (4.9% of studies; see figure 2). The median number of indicators used 
was 3 (inter-quartile range=2). 
INSERT Figure 2: Number of indicators used across studies 
The most frequently reported indicators used to define BWI were presence of bacteria in the wound, 
identified from swab of pus or exudate (n=25; 61.0% studies), change in colour or volume of exudate 
(n=25; 48.8%), spreading erythema (n=16; 39.0%), oedema (n=10; 24.4%),  pyrexia and pain (n=9; 
22.0%  respectively).  
Seven studies (17.0%) defined BWI using indicators that represented a group of signs and symptoms:  
Cellulitis was used as an indicator to define BWI in five studies[52-56] (12.2%), and ‘clinical 
signs’[57] and ‘biological markers’[57] in one study (2.4% respectively). Administration of 
antibiotics was used to define presence of BWI in two studies (4.9%)[58, 59].  
11 of 41 studies (26.8%) studies reported the use of only one indicator[13, 14, 42, 45, 49, 55, 60-66]. 
Of these, four used bacteria in the wound  identified from  swab of pus or exudate [13, 62, 64, 65] and 
six used wound biopsy or tissue culture.[42, 45, 60, 61, 63, 66] The remaining study using describing 
the use of a single indicator to define BWI, defined it as cellulitis[55]; it should be noted that this 
represents a collection of signs and symptoms. 
 





i) Whether the same indicators were used to define BWI across studies.  
Thirteen studies (31.7%) had the same definition of BWI as at least one other study. In four of the 11 
studies using a single indicator to define BWI, it was defined as presence of bacteria in the wound, 
identified from swabs of the wound or pus.[13] [62, 64, 65] In six of the 11 studies (54.5%)  defining 
BWI with a single indicator, it was defined as bacterial presence indicated from wound biopsy or 
tissue culture,[42, 45, 60, 61, 63, 66] with three of these studies stating that wound infection was 
defined as >105 colony forming units per gram of tissue[14, 42, 45]. Of the nine studies using two 
indicators to define BWI, two (22.2%) used the same indicators to define it: presence of bacteria in 
the wound from swabs, and a change in colour or the quantity of exudate.[73, 74] 
 
v) Numerical values for indicators used to determine presence of BWI  
Of the 25 studies using presence of bacteria from wound swabs to define BWI, six (24.0%) described 
the numerical values used to determine presence of BWI (>105 microbes per gram of tissue[59] [47] 
[85] [65] [56, 75]).  For tissue cultures, five of eight studies reported numerical values used to 
determine presence of BWI (>105 colony forming units per gram of tissue[45, 60] [42] [66]). The 
remaining studies did not report what numerical values were used for presence of bacteria in the 
wound.  One of the nine studies (11.1%) using pyrexia reported the numerical values used to 
determine ‘fever’ and ‘high fever’ (>37.4°c and >38°c respectively[69]).  
 
vi) Whether a method for combining data from several indicators to determine presence of BWI was 
specified (e.g. a count of the number of indicators present or a weighted scoring system) 
Thirty-one studies (75.6%) used more than one indicator to define BWI. Of these, 10 (32.3%) 
reported a method for rating or combining data from the multiple indicators used to determine 
whether BWI was present.  In four studies (40.0%) BWI was evaluated by counting the number of 




This systematic review was undertaken to identify whether BWI is defined, and where defined, 
whether there is variation in the indicators used to define it across burn care studies.  Of 71 included 
studies, 59 (83.1%) described that they planned to assess BWI as an outcome in the study methods. Of 
these 44 (62.0% of all studies) reported how they had defined BWI; six studies (13.6%) used a 
consensus tool, and 41 (93.2%) described the indicators used to define BWI. Twenty-seven different 
indicators of BWI were used across studies. Between one and nine indicators were used to define 
BWI across studies (median=3; IQR=2).  Only 13 of 41 (31.7%) studies reporting the indicators that 
they used to define BWI used the same indictors as at least one other study.  
There are two key findings from this review. The first is that in 38% of studies reporting data on BWI, 
it was not stated how this outcome was defined, and 16.9% of studies reported data about BWI 
without describing it as a study outcome in their methods. One quarter (25.4%) of studies describing 
BWI as an assessed study outcome failed to report how they had defined it.  Where BWI was defined, 
a small number of studies used imprecise terms, including ‘cellulitis’, ‘wound signs’, and ‘biological 
markers’. These terms may represent numerous different indicators that were assessed. The lack of 
specificity identified in the some definitions of BWI in the current review replicates the findings of 
other systematic reviews in burn care[87], where poor-quality reporting of trial methodology has been 
identified. This lack of clarity of outcome definition will prevent reproducibility of a study’s findings 
about intervention effectiveness[88]. 
The second finding is that across studies providing a definition of BWI, there was considerable 
heterogeneity in how it was defined. This variation in the indicators used to define wound infection 
has also been found in systematic reviews of surgical site infections[89] and healthcare associated 
infections[90]. This will limit the validity of evidence syntheses using data from these studies. If data 
from studies with varying outcome definitions are synthesised, the review’s findings may not 
represent the ‘truth’ about the effectiveness of the intervention. This problem has been highlighted in 
recent Cochrane Reviews of the use of antibiotic prophylaxis[91], antiseptics[92], and 
 
 
immunonutrition[93] for patients with burns, in which the authors reported that the validity of their 
findings was compromised due to limited reporting and varied indicators applied to define BWI.  
Consensus statements have been developed to standardise the diagnosis of BWI. However, only six of 
the 71 included studies (8.5%) reported their use. This may relate to practical limitations of these 
tools. These include the use of wound biopsy[3] [9], which is costly,may cause scarring, and is 
infrequently used in some health care systems such as the UK NHS. Further potential limitations are 
the inclusion of indicators that are sensitive signs of infection but rarely observed in patients[10], and 
a focus on wound-related signs without reference to key systemic signs of infection (e.g. pyrexia, 
leucocytosis)[10]. 
A further funding from this this review is a potential over-reliance on non-quantitative and 
quantitative bacterial counts from wound swabs and tissue sampling. Many of the studies defining 
BWI using wound swabs and tissue sampling used quantitative microbiological assessment of the 
wound, commonly as the only indicator of BWI. Furthermore, many of the included studies defined 
BWI as >105 bacteria/ colony forming units per gram of tissue. Clinically relevant infection that 
requires treatment should not be identified without referring to other clinical signs and symptoms of 
BWI. A recent systematic review of human studies investigating the reliability of wound swabs and 
biopsies found that more than one sample of the wound may be needed to obtain an accurate estimate 
of bacterial load, correlation between swabs and biopsies is frequently poor, and that clinical signs 
and symptoms should be referred to in addition to quantitative microbiology, since 13 studies found 
no correlation of biopsy findings with clinical outcomes. A further literature review supports the view 
that quantitative microbiology should not be used without reference to clinical signs and symptoms, 
and is suggestive that the 105colony forming units/gram of tissue cut-off is arbitrary, particularly since 
clinically relevant infection is more likely to be found at higher bacterial concentrations. [94, 95]. 
These data suggest that quantitative microbiology alone may be an unreliable indicator of BWI and 
may overstate the incidence of BWI, since bacteria are frequently present in burn wounds without 
being clinically relevant[1] (wound colonisation).  
 
 
This review employed a systematic approach to the identification and selection of studies reporting 
BWI as an outcome. The use of four databases to identify RCTs, observational studies, case control 
studies and protocols provides a comprehensive review of how BWI has been defined across studies. 
Limitations include the exclusion of studies published before 2010. This limit was placed to ensure 
that we identified reports relating to current BWI diagnostic practices. Studies that were not published 
in English were excluded due to funding constraints. While unpublished literature was requested from 
interested parties, no additional studies or work in progress reports were put forward.   
 
Clinical decision-making about effective treatments for BWI requires that evidence is synthesised 
across relevant studies. Inconsistent definition and measurement of BWI creates ‘noise’ in the data 
which may obscure the true effect of interventions, whereby interventions that are effective may not 
be identified. There is a need to improve the consistency of how BWI is defined, and for this to be 
reported in the study methods and results. However, identification of a consistent definition is difficult 
as there no agreed objective diagnostic method for determining presence of clinically relevant BWI. 
Until an objective method for diagnosing BWI is available, agreement about a minimum set of 
indicators to be reported when assessing BWI as an outcome is necessary to allow comparison and 
collation. One means to do this is to use published literature and expert consensus to identify a 
minimum set of BWI indicators (a Core Indicator Set) that are considered important to report in future 
research trials, and that are most suggestive of BWI infection. This consensus methodology has been 
used to identify diagnostic indicators in other infection domains, such as bone and joint infections, 
and renal cyst infections[96, 97]. By defining a Core Indicator Set, BWI outcomes and the indicators 
used to define it can be compared across burn care trials to reliably synthesise the data and identify 





This systematic review of how BWI is defined in trials of interventions for patients with burns has 
shown that 38% of included studies did not report how they defined BWI, that there is considerable 
heterogeneity in the indicators used, and limited use of consensus tools. This inconsistency in 
definition of BWI will limit the validity of evidence syntheses, preventing the identification of the 
most effective treatments for patients with burns. Until there is an objective method to diagnose 
clinically relevant BWI, development of a minimum core set of indicators (CIS) to standardise 
reporting in trials reporting a BWI outcome is needed. 
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